Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.China Sky One Medical has developed a propyl gallate injection for the treatment of acute cerebral infarction, coronary heart disease, thrombosis, dysmenorrheal and nephropathy.
Subscribe to our email newsletter
Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical, has recently completed R&D for eight different types of injections, obtaining production approval for three injections, including the propyl gallate injection.
Yan-Qing Liu, chairman, CEO and president of China Sky One Medical, said: “We are now in the last stage before formal production, and expect to launch the product in the middle of August.”